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Article abstract—Cognitive and functional outcomes are of primary interest
in the design of efficacy trials in HIV-associated cognitive impairment. In a
longitudinal cohort study, weak associations were found between measures of
cognitive performance and commonly used measures of daily functioning
(mostly self-report measures) in HIV-infected individuals. Modifications of
current functional scales or new functional instruments are needed to assess
the clinical relevance of cognitive changes in clinical trials of HIV-associated
cognitive impairment.
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Cognitive impairment is a common sequela of HIV-1
infection1 that continues to exist despite the current
use of potent antiretroviral therapy. Clinical trials in
HIV-associated cognitive impairment have been
largely safety and tolerability studies, relatively
short in duration.2-4 However, as we move from these
early phase studies to larger efficacy trials, cognitive
and functional outcomes are of primary interest. Un-
fortunately, there are no available measures of func-
tion specifically designed to assess performance in
HIV-infected subjects with cognitive impairment.
Using data from the Dana cohort,5 we investigated
whether or not commonly used functional measures
were associated with cognitive performance.
Design and method. The characteristics of the Dana
cohort have been previously described.5 Based on a modi-
fication of the American Academy of Neurology (AAN)
recommendations5 and previous clinical trials in HIV-
associated cognitive impairment,4 we defined mild cogni-
tive impairment as performance that was 2 SD below the
appropriate means on one test (which could not be timed
gait) or 1 SD below the mean on at least two tests. Subjects
having no test scores 2 SD below the mean and no more
than one test score 1 SD below the mean were classified as
not impaired (some of these subjects might have met AAN
criteria for minor cognitive/motor disorder5). In this study,
we classified the remaining subjects based only on the
number of tests on which scores were 2 SD below the mean
as moderately impaired (two or three tests 2 SD below thee
mean) or as severely impaired (four or more tests 2 SD
below the mean). It was felt that a test 2 SD below the
mean would represent a definite abnormal result and that
if 50% (four) or more of the neuropsychological tests were 2
SD below the mean the cognitive performance would be
severely impaired.
Average z scores were created from the neuropsycholog-
ical test battery with the aid of a principal component
factor analysis using varimax rotation. Three factors were
identified that accounted for 68.4% of the total variance:
Attention/Memory (Rey Auditory Verbal Learning Test—
total score, Trial 5 score, Recall after Interference, Delayed
Recall, and Correct Recognition), Psychomotor Speed
(Grooved Pegboard, dominant and nondominant hands,
and Symbol Digit Modalities Test), and Executive Func-
tion (Rey Complex Figure Copy and Immediate Recall,
Odd-Man-Out Test, and Verbal Fluency).
Functional measures included the Instrumental Activ-
ity of Daily Living (IADL) scales of Lawton and Brody,6 the
Katz ADL/Lawton Self-Maintenance scale (SMADL),7 the
Role Functioning items of the Medical Outcomes Study
(MOS),8 the MOS Physical Function Subscale,8 and the
Karnofsky Performance Scale.9 In addition, the Center for
Epidemiologic Studies–Depression Scale (CES-D) was used
to assess mood.
A detailed description of the statistical methods used
can be found on the web site. Brief descriptions follow in
Results and the tables.
Results. Demographic and clinical characteristics of the
participants at baseline are shown in table 1. Functional
performance tended to decline with increasing degree of
cognitive impairment at baseline (table 2), in particular
with regard to Role Function, Physical Function, and
Karnofsky Performance Scale score. These differences
were attenuated after adjustment for other baseline co-
variates. The percentages of subjects demonstrating an
IADL deficit were as follows: unimpaired, 40%; mild, 41%;
moderate, 34%; severe, 56%. The percentages of subjects
demonstrating an SMADL deficit were as follows: unim-
paired, 10%; mild, 9%; moderate, 12%; severe, 20%.
Of the 270 subjects included in the baseline analyses,
138 had a 1-year follow-up visit, 102 did not return for the
1-year visit (46 due to death, 31 due to loss to follow-up, 11
due to withdrawal of consent, 11 for other reasons, and
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three for unknown reasons), and 30 were enrolled into the
study too late to have a 1-year follow-up visit. The dropout
rates before 1 year were the following: unimpaired, 36%;
mild, 39%; moderate, 53%; severe, 52%. As expected, those
who dropped out before 1 year tended to have more ad-
vanced HIV infection and lower Physical Function scores
than those who had a 1-year visit (additional material
related to this article can be found on the Neurology Web
site. Go to www.neurology.org and scroll down the Table of
Contents for this issue to find the title link for this article).
In terms of cognitive function, the two groups tended to
differ only in average Psychomotor Speed z scores (p 5
0.07; additional information related to this article can be
found on the Neurology Web site) .
Cognitive and functional performance tended to be ei-
ther stable or improved after 1 year of follow-up (table 3).
Seventy percent (70%) of subjects changed by at most 1
point on the IADL scale, and 87% of subjects did not
change at all on the SMADL scale. The improvement in
Attention/Memory z scores tended to be more prominent
for the groups with mild/moderate cognitive impairment,
and the improvement in the Executive Function and Psy-
chomotor Speed z scores tended to be more prominent for
the groups with moderate/severe cognitive impairment.
The improvement in Role Function was consistent across
the cognitive impairment groups (additional information
related to this article can be found on the Neurology Web
site. Go to www.neurology.org and scroll down the Table of
Contents for this issue to find the title link for this article).
Overall, the correlations between the 1-year changes in
function (Karnofsky Performance Scale, Role Function,
Physical Function) and the 1-year changes in cognitive
performance (domain z scores) were weak, with only one
correlation (between Karnofsky Performance Scale score
and the Psychomotor Speed z score, r 5 0.26, p 5 0.003)
being .0.20. Within the subgroup of subjects with mild










Sex, % men 76 79 76 84
Ethnicity, white/black/Hispanic/others, % 59/34/5/2 48/40/7/4 49/39/10/1 36/60/4/0
Age, y, mean (SD) 38.8 (7.5) 40.7 (7.6) [0.11] 39.1 (7.5) [0.85] 40.6 (7.9) [0.30]
Education, y, mean (SD) 13.0 (2.6) 13.6 (2.8) [0.20] 14.0 (3.2) [0.04] 13.7 (3.8) [0.30]
UPDRS, mean (SD) 2.8 (5.3) 4.3 (5.2) [0.16] 5.9 (7.8) [0.01] 10.9 (12.3) [0.0001]
CES-D, mean (SD) 17.6 (9.6) 19.6 (11.4) [0.21] 22.0 (10.6) [0.01] 28.6 (12.0) [,0.0001]
CD41 T-cell count/mm3, mean (SD) 211.2 (222.2) 143.7 (162.7) [0.02] 187.7 (155.4) [0.99] 183.6 (168.1) [0.83]
Hemoglobin, g/dL, mean (SD) 13.1 (1.6) 12.9 (1.8) [0.50] 12.6 (2.1) [0.09] 12.4 (2.0) [0.10]
Two-tailed p values for comparison between patients with normal cognitive performance and those with cognitive impairment are
shown in brackets, as obtained from t-tests. p Values of ,0.017 are considered to be significant, after Bonferroni adjustment for multi-
ple comparisons.
UPDRS 5 Unified Parkinson’s Disease Rating Scale (motor component); CES-D 5 Center for Epidemiologic Studies–Depression Scale.












Role Function 10.9 (2.2) 10.5 (2.3) [0.23] 10.1 (2.2) [0.06] 9.6 (2.5) [0.02]
Physical function 21.2 (4.9) 21.5 (4.2) [0.69] 19.8 (4.8) [0.08] 18.6 (6.0) [0.03]
Karnofsky 85.2 (12.5) 83.8 (12.0) [0.51] 83.1 (15.1) [0.34] 77.0 (16.8) [0.008]
Adjusted analyses†
Role Function 11.0 10.9 [0.61] 10.7 [0.30] 10.6 [0.42]
Physical function 20.3 21.6 [0.05] 19.9 [0.57] 21.1 [0.49]
Karnofsky 84.6 84.2 [0.81] 85.0 [0.87] 80.7 [0.20]
* Values are expressed as means (SD) [p value]. p Values for comparison between patients with normal cognitive performance and
those with cognitive impairment are shown in brackets, as obtained from t-tests. p Values of ,0.017 are considered to be significant,
after Bonferroni adjustment for multiple comparisons.
† Values are adjusted group means. Group comparisons were adjusted for age, sex, years of education, Center for Epidemiological Stud-
ies–Depression Scale, CD4 count (log transformed), hemoglobin level, number of medications (square root transformed), and number
of AIDS diagnoses (dichotomized as 0–1 vs .1).
Functional score ranges: Role Function, 7–14; Physical Function, 9–27; Karnofsky, 0–100. A higher functional score indicates better
performance.
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cognitive impairment, the partial correlations (adjusted for
CES-D, CD4 count, and hemoglobin) between the change
in Executive Function z score and changes in the func-
tional tests were as follows: 0.44 (p 5 0.007) for Karnofsky
Performance Scale score, 0.33 (p 5 0.05) for Role Function,
and 0.37 (p 5 0.02) for Physical Function. For subjects
with moderate cognitive impairment, significant partial
correlations were observed between the change in Karnof-
sky Performance Scale score and both the Attention/
Memory z score (r 5 0.52, p 5 0.009) and the Psychomotor
Speed z score (r 5 0.54, p 5 0.01).
Discussion. In the current study, we investigated
the relationship between the degree of HIV-
associated cognitive impairment, as defined by neu-
ropsychological test performance, and commonly
used measures of daily function. Our results show
that at baseline, IADL6 and SMADL7 had the weak-
est relationships with cognitive performance. The
other three measures, Role Function,8 Physical Func-
tion,8 and the Karnofsky Performance Scale,9 indi-
cated that functional impairment tended to be
present only in patients with severe cognitive dys-
function. However, when other factors such as age,
education, mood, and immune function were taken
into account, none of the functional measures
showed a significant relationship with cognitive per-
formance (see table 2).
A 12-month evaluation showed a weak association
between changes in functional measures and
changes in cognition. Conversely, the cognitive sub-
group analyses showed some significant but nonuni-
form relationships between changes in cognition and
changes in functional measures. For example, the
Karnofsky Performance Scale was the functional
measure that correlated best with Executive Func-
tion (mild cognitive impairment subgroup) and with
Attention/Memory and Psychomotor Speed (moder-
ate cognitive impairment subgroup).
The five functional measures used in this study,
with the exception of the Karnofsky scale, are self-
-report measures. It may be anticipated that subjects
with more severe cognitive impairment may not real-
ize the extent of their functional decline. This may
explain in part the results of the cognitive subgroup
analyses, suggesting a better correlation between
changes in some cognitive domains and changes in
the Karnofsky score (scale scored by physician or
nurse). Conversely, the premorbid functional status
probably influenced the subject assessment of func-
tional changes.
The longitudinal analyses were limited in part by
an attrition of 42.5% at 1 year. The observed cogni-
tive improvement may be a spurious result that
could be explained by an enrichment of the cohort of
subjects with better cognitive performance after the
withdrawal of those with worse performance. Also,
regression to mean may be responsible for the im-
provement. This questionable cognitive improvement
may make it difficult to specify a reasonable effect
size to try to detect when determining the appropri-
ate sample size for a clinical trial.
Enrolling into trials HIV subjects with cognitive
impairment based on neuropsychological test scores
rather than the definition of dementia offers some
advantages. Dementia, by definition, requires loss of
function. Unfortunately, attribution of loss of func-
tion to cognitive impairment is a difficult task when
applied to a systemic disease such as HIV infection.
Furthermore, dementia scales may be prone to sub-
stantial variability.10 In addition, subjects in earlier
stages of cognitive impairment may be more likely to
respond to therapy. Neuropsychological test batter-
ies are well standardized, thus less prone to subjec-
tive interpretation, and can be easily used in
multicenter studies. However, modification of cur-
rent functional scales or new instruments that corre-
late better with cognitive performance are needed to
assess the clinical relevance of impairment (and im-
provement) on neuropsychological tests.
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Executive function, z score 0.14 (0.87) 0.09
Attention/memory, z score 0.30 (0.97) 0.0007
Psychomotor Speed, z score 0.15 (1.22) 0.17
Karnofsky 20.7 (14.8) 0.58
Role Function 0.4 (2.0) 0.02
Physical Function 0.2 (4.2) 0.68
A positive sign indicates improvement from baseline assessment.
p Values are from two-tailed paired t-tests of the null hypothesis
of zero mean change.
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Neuro Images
Pulmonary arteriovenous fistula and
brain abscess
David C. Preston, MD, Barbara E. Shapiro, MD, PhD
Cleveland, OH
A 23-year-old woman presented with 3 days of headache
followed by complex partial seizures. Stereotactic aspira-
tion of a large right temporal mass revealed purulent ma-
terial with Gram-positive cocci (Streptococcus millieri).
Chest radiograph and CT scan demonstrated a pulmonary
arteriovenous fistula (PAVF). PAVF are low resistance,
abnormal connections between a pulmonary artery and
distended vein. They may occur as an isolated entity or
associated with hereditary hemorrhagic telangiectasia (Os-
ler Weber Rendu syndrome). PAVF often present with neu-
rologic symptoms, usually stroke, TIA, or brain abscess
from the right to left shunt that bypasses the normal filter-
ing action of the lungs.
1. Moussouttas M, Fayad P, Rosenblatt M, et al. Pulmonary arteriovenous
malformations: cerebral ischemia and neurologic manifestations. Neurol-
ogy 2000;55:959–964.
2. Swanson KL, Prakash UB, Stanson AW. Pulmonary arteriovenous fistu-
las: Mayo Clinic experience, 1982–1997. Mayo Clin Proc 1999;74:671–
680.
Figure. (A) Axial T2-weighted MRI—right temporal brain abscess with surrounding edema; (B) chest x-ray shows mass at right base; (C)
axial chest CT—enhancing vascular mass at right base; (D) three-dimensional chest CT reconstruction demonstrates a right pulmonary
arteriovenous fistula.
418 Copyright © 2001 by AAN Enterprises, Inc.
DOI 10.1212/WNL.56.3.415
2001;56;415-418 Neurology 
G. Schifitto, K. Kieburtz, M.P. McDermott, et al. 
outcomes
Clinical trials in HIV-associated cognitive impairment: Cognitive and functional




including high resolution figures, can be found at:
Supplementary Material
 http://www.neurology.org/content/suppl/2001/02/05/56.3.415.DC1
Supplementary material can be found at: 
References
 http://www.neurology.org/content/56/3/415.full.html##ref-list-1
This article cites 9 articles, 3 of which you can access for free at: 
Citations
 http://www.neurology.org/content/56/3/415.full.html##otherarticles




its entirety can be found online at:




Information about ordering reprints can be found online:
Online ISSN: 1526-632X.
1951, it is now a weekly with 48 issues per year. Copyright . All rights reserved. Print ISSN: 0028-3878. 
® is the official journal of the American Academy of Neurology. Published continuously sinceNeurology 
